S&P 500   3,376.20 (+1.28%)
DOW   27,940.32 (+0.92%)
QQQ   270.97 (+2.18%)
AAPL   445.21 (+1.76%)
MSFT   207.45 (+2.00%)
FB   262.67 (+2.55%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,142.00 (+1.99%)
NVDA   444.95 (+2.52%)
CGC   17.13 (+1.06%)
BABA   252.60 (+1.68%)
TSLA   1,477.83 (+7.53%)
GE   6.67 (-0.89%)
MU   48.02 (+0.54%)
AMD   79.93 (+3.97%)
T   30.18 (-0.07%)
F   7.14 (-1.24%)
ACB   9.81 (-2.10%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   131.95 (+1.12%)
BAC   26.97 (+0.19%)
BA   178.69 (-0.80%)
S&P 500   3,376.20 (+1.28%)
DOW   27,940.32 (+0.92%)
QQQ   270.97 (+2.18%)
AAPL   445.21 (+1.76%)
MSFT   207.45 (+2.00%)
FB   262.67 (+2.55%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,142.00 (+1.99%)
NVDA   444.95 (+2.52%)
CGC   17.13 (+1.06%)
BABA   252.60 (+1.68%)
TSLA   1,477.83 (+7.53%)
GE   6.67 (-0.89%)
MU   48.02 (+0.54%)
AMD   79.93 (+3.97%)
T   30.18 (-0.07%)
F   7.14 (-1.24%)
ACB   9.81 (-2.10%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   131.95 (+1.12%)
BAC   26.97 (+0.19%)
BA   178.69 (-0.80%)
S&P 500   3,376.20 (+1.28%)
DOW   27,940.32 (+0.92%)
QQQ   270.97 (+2.18%)
AAPL   445.21 (+1.76%)
MSFT   207.45 (+2.00%)
FB   262.67 (+2.55%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,142.00 (+1.99%)
NVDA   444.95 (+2.52%)
CGC   17.13 (+1.06%)
BABA   252.60 (+1.68%)
TSLA   1,477.83 (+7.53%)
GE   6.67 (-0.89%)
MU   48.02 (+0.54%)
AMD   79.93 (+3.97%)
T   30.18 (-0.07%)
F   7.14 (-1.24%)
ACB   9.81 (-2.10%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   131.95 (+1.12%)
BAC   26.97 (+0.19%)
BA   178.69 (-0.80%)
S&P 500   3,376.20 (+1.28%)
DOW   27,940.32 (+0.92%)
QQQ   270.97 (+2.18%)
AAPL   445.21 (+1.76%)
MSFT   207.45 (+2.00%)
FB   262.67 (+2.55%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,142.00 (+1.99%)
NVDA   444.95 (+2.52%)
CGC   17.13 (+1.06%)
BABA   252.60 (+1.68%)
TSLA   1,477.83 (+7.53%)
GE   6.67 (-0.89%)
MU   48.02 (+0.54%)
AMD   79.93 (+3.97%)
T   30.18 (-0.07%)
F   7.14 (-1.24%)
ACB   9.81 (-2.10%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   131.95 (+1.12%)
BAC   26.97 (+0.19%)
BA   178.69 (-0.80%)
Log in

NASDAQ:CGENCompugen Stock Price, Forecast & News

$16.81
+0.53 (+3.26 %)
(As of 08/12/2020 11:10 AM ET)
Add
Compare
Today's Range
$16.50
Now: $16.81
$17.05
50-Day Range
$14.04
MA: $15.34
$16.85
52-Week Range
$3.41
Now: $16.81
$17.85
Volume21,206 shs
Average Volume1.34 million shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.77
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Read More
Compugen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.80 million
Book Value$1.89 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Employees89
Market Cap$1.15 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$16.81
+0.53 (+3.26 %)
(As of 08/12/2020 11:10 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Compugen (NASDAQ:CGEN) Frequently Asked Questions

How has Compugen's stock been impacted by COVID-19 (Coronavirus)?

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CGEN stock has increased by 42.1% and is now trading at $16.81.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Compugen?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Compugen
.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Compugen
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.02.
View Compugen's earnings history
.

What price target have analysts set for CGEN?

8 equities research analysts have issued 1-year target prices for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they expect Compugen's stock price to reach $19.25 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts' price targets for Compugen
.

Has Compugen been receiving favorable news coverage?

News headlines about CGEN stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Compugen earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Compugen
.

Are investors shorting Compugen?

Compugen saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 3,970,000 shares, an increase of 20.3% from the January 31st total of 3,300,000 shares. Based on an average trading volume of 420,400 shares, the days-to-cover ratio is presently 9.4 days.
View Compugen's Short Interest
.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), QUALCOMM (QCOM), Splunk (SPLK), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM) and Etsy (ETSY).

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
  • Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (0.85%), Taylor Frigon Capital Management LLC (0.74%), Rothschild Investment Corp IL (0.50%), Defender Capital LLC. (0.31%), Phoenix Holdings Ltd. (0.29%) and Swiss National Bank (0.25%).

Which major investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Defender Capital LLC., Raymond James & Associates, and Rothschild Investment Corp IL.

Which major investors are buying Compugen stock?

CGEN stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Swiss National Bank, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Aigen Investment Management LP, Virtus ETF Advisers LLC, HighTower Advisors LLC, and Phoenix Holdings Ltd..

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $16.81.

How big of a company is Compugen?

Compugen has a market capitalization of $1.15 billion and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.